| Name | Title | Contact Details |
|---|
Formycon ist ein führender und unabhängiger Entwickler von qualitativ hochwertigen biopharmazeutischen Nachfolgeprodukten, sogenannten Biosimilars.
BioClin Therapeutics, Inc. is a privately-held biotechnology developing biologics to address medical conditions where there is significant unmet need. Our lead program is a human monoclonal antibody, B-701, that targets and blocks the activity of FGFR3 (fibroblast growth factor receptor 3) and is the most advanced FGFR3-specific antagonist in development. B-701 has been tested in two Phase 1 clinical trials involving 40 patients and demonstrated potential efficacy in patients with metastatic bladder cancer who were receiving it as 2nd line therapy.
Sentigen Biosciences is a Phillipsburg, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
BioGenex Laboratories, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Ventana Clinical Research Corp is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.